Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Joly

Showing results (221-230 of 347) with videos related to

Pageof 35
Sort By:
Acta Neuropathologica|January 5, 2018
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degenerationMathilde Small, Isabelle Treilleux, Coline Couillault, et al.
European Urology|June 9, 2021
Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN TrialJean Courcier, Cécile Dalban, Brigitte Laguerre, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2016
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trialRoman Rouzier, Sébastien Gouy, Frédéric Selle, et al.
Gynecologic Oncology|November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancerKatherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
Neuroscience and Biobehavioral Reviews|September 26, 2019
How to assess and manage cognitive impairment induced by treatments of non-central nervous system cancerMarie Lange, Hélène Castel, Johan Le Fel, et al.
The Oncologist|June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit StudyFelicia T Roncolato, Florence Joly, Rachel O'Connell, et al.
Plos One|July 31, 2024
Exploration of effects of galvanic vestibular stimulation on circadian rhythms and its associations with sleep and spatial memory in patients with breast cancer: The ICANSLEEP-2 protocolMelvin Galin, Laura de Girolamo, Bénédicte Clarisse, et al.
European Urology Oncology|October 9, 2023
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 TrialEmilien Billon, Cécile Dalban, Stephane Oudard, et al.
BMC Cancer|December 1, 2023
Effects of sleep disturbances and circadian rhythms modifications on cognition in breast cancer women before and after adjuvant chemotherapy: the ICANSLEEP-1 protocolClara Elia, Laura de Girolamo, Bénédicte Clarisse, et al.
Psycho-Oncology|October 14, 2020
Differentiation of groups of patients with cognitive complaints at breast cancer diagnosis: Results from a sub-study of the French CANTO cohortIsabelle Hardy-Leger, Cécile Charles, Marie Lange, et al.
Pageof 35

Showing results (221-230 of 347) with videos related to

Sort By:
Pageof 35
Acta Neuropathologica|January 5, 2018
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degenerationMathilde Small, Isabelle Treilleux, Coline Couillault, et al.
European Urology|June 9, 2021
Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN TrialJean Courcier, Cécile Dalban, Brigitte Laguerre, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2016
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trialRoman Rouzier, Sébastien Gouy, Frédéric Selle, et al.
Gynecologic Oncology|November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancerKatherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
Neuroscience and Biobehavioral Reviews|September 26, 2019
How to assess and manage cognitive impairment induced by treatments of non-central nervous system cancerMarie Lange, Hélène Castel, Johan Le Fel, et al.
The Oncologist|June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit StudyFelicia T Roncolato, Florence Joly, Rachel O'Connell, et al.
Plos One|July 31, 2024
Exploration of effects of galvanic vestibular stimulation on circadian rhythms and its associations with sleep and spatial memory in patients with breast cancer: The ICANSLEEP-2 protocolMelvin Galin, Laura de Girolamo, Bénédicte Clarisse, et al.
European Urology Oncology|October 9, 2023
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 TrialEmilien Billon, Cécile Dalban, Stephane Oudard, et al.
BMC Cancer|December 1, 2023
Effects of sleep disturbances and circadian rhythms modifications on cognition in breast cancer women before and after adjuvant chemotherapy: the ICANSLEEP-1 protocolClara Elia, Laura de Girolamo, Bénédicte Clarisse, et al.
Psycho-Oncology|October 14, 2020
Differentiation of groups of patients with cognitive complaints at breast cancer diagnosis: Results from a sub-study of the French CANTO cohortIsabelle Hardy-Leger, Cécile Charles, Marie Lange, et al.
Pageof 35